local_hospital

Unidade Local De Saude Do Alto Ave E.P.E.

Address
lock Available on a paid plan

Cardiovascular Diseases and Heart Failure Research at Unidade Local De Saude Do Alto Ave E.P.E.

This site in Guimaraes, Portugal is active in cardiology studies focused on cardiovascular diseases, including acute coronary syndrome, hypertension, atherosclerotic cardiovascular disease, heart failure, and transthyretin amyloid cardiomyopathy. The trials are designed to test new treatments, reduce major cardiac events, and improve long-term disease control.

  • Preventing heart attacks, stroke, and other major cardiovascular events
  • Evaluating therapies for heart failure and cardiomyopathy
  • Studying lipid-lowering and risk-reduction strategies in high-risk patients

Research here also includes imaging-based assessment of treatment response and studies aimed at better understanding cardiac function and disease progression.

Oncology and Precision Cancer Treatment

A major share of the research landscape covers neoplasms, especially breast cancer, gastric and gastroesophageal junction cancer, non-small cell lung cancer, small cell lung cancer, metastatic colorectal cancer, and urothelial carcinoma. These trials are centered on evaluating new targeted therapies and combinations intended to improve survival and disease control.

  • Testing targeted approaches in HER2-positive and hormone receptor-positive breast cancer
  • Assessing new treatment options for advanced gastric cancer and GEJ adenocarcinoma
  • Studying novel strategies for advanced lung cancer and metastatic solid tumors

The site’s oncology portfolio reflects a strong interest in personalized medicine, with studies aimed at improving treatment effectiveness and delaying cancer recurrence.

Digestive System Diseases, Liver Disorders, and Inflammatory Bowel Disease

Clinical trials in digestive system diseases include Crohn’s disease, ulcerative colitis, non-alcoholic steatohepatitis, primary sclerosing cholangitis, and primary biliary cholangitis. The research is focused on improving symptom control, reducing inflammation, and testing treatments that may slow disease progression or improve liver health.

  • Evaluating therapies for inflammatory bowel disease
  • Studying treatment options for NASH and other chronic liver conditions
  • Assessing long-term safety and effectiveness of emerging digestive disease therapies

This area includes work on both gastrointestinal inflammation and metabolic liver disease, showing broad interest in chronic digestive and hepatology research.

Respiratory Diseases, Allergy, and Airway Inflammation

The site also supports trials in respiratory tract diseases, including chronic obstructive pulmonary disease, severe asthma, bronchiectasis, pneumonia, and chronic rhinosinusitis. These studies aim to improve breathing symptoms, lower exacerbation rates, and assess new anti-inflammatory or supportive therapies.

  • Testing treatments for COPD and asthma control
  • Evaluating therapies to reduce flare-ups and improve lung function
  • Studying approaches for sinus and airway inflammation

Research in this field spans chronic lung disease and upper-airway disorders, with a focus on better day-to-day symptom management.

Metabolic and Endocrine Research

Trials in nutritional and metabolic diseases include obesity, type 2 diabetes, familial chylomicronemia syndrome, and dyslipidemia. These studies are designed to evaluate therapies that may improve metabolic health, reduce cardiovascular risk, and protect against complications such as diabetic eye disease.

  • Exploring treatments for obesity and metabolic risk
  • Assessing therapies for type 2 diabetes and related complications
  • Studying lipid and triglyceride lowering strategies

The metabolic portfolio connects closely with cardiovascular research, reflecting the overlap between blood sugar control, weight management, and heart health.

Nervous System and Mental Health Studies

Research in nervous system diseases and mental disorders includes Alzheimer’s disease, Parkinson’s disease, migraine, multiple sclerosis, and psychosis related to dementia. These trials are aimed at improving symptoms, preserving function, and evaluating new options for cognitive and behavioral conditions.

  • Studying treatments for Alzheimer’s-related cognitive and behavioral symptoms
  • Evaluating options for Parkinson’s disease and migraine
  • Assessing therapies for neurologic recovery after stroke or brain injury

This area includes both neurodegenerative disease and symptom-focused care, with an emphasis on quality of life and long-term management.

Immune-Mediated, Rheumatologic, and Skin Disease Research

The site conducts studies in immune system diseases, musculoskeletal diseases, and skin and connective tissue diseases, including rheumatoid arthritis, systemic lupus erythematosus, hidradenitis suppurativa, psoriasis, and ulcerative colitis. These trials generally aim to reduce inflammation, relieve symptoms, and improve long-term disease control.

  • Testing new therapies for chronic autoimmune inflammation
  • Evaluating treatments for rheumatoid arthritis and lupus
  • Studying options for psoriasis and other inflammatory skin conditions

The research portfolio highlights a broad interest in immune-driven diseases that affect the joints, skin, and internal organs.

Site Overview

assignment
115
connected trials
corporate_fare
58
sponsors
science
190
IMPs

Activity Indicator

Last 6 months

9
Trials started
-47% vs previous period.
17
Trials started 6–12 months ago
115
Total trials linked
Highly Active
trending_downDeclining-47%
2
4
2
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 14 therapeutic areas and 15 of 190 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 171 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
47
Sponsors (total)
58
Active sponsors
33

Sponsor Network

Top 33 by active trials.

lock +32 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +22 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 84 other sites in Portugal

description
Trial volume
115
Outperforms 89% of sites
public
Therapeutic diversity
14areas
Outperforms 86% of sites
groups
Sponsor diversity
58sponsors
Outperforms 92% of sites

Therapeutic Area Benchmark — Portugal

Select a therapeutic area to compare against other sites in Portugal.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Portugal

Market Share

Country: Portugal

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Unidade Local De Saude Do Alto Ave E.P.E.

lock Showing 1 of 115 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4)Xenon Pharmaceuticals Inc.Phase IIIRecruitingFeb 2024

IMP list

lock Showing 1 of 190 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Oxaliplatin6Unknown2018-09-212025-07-31

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.